Benzinga | Oct 28, 2021 04:03PM EDT

PTC Therapeutics Q3 EPS $(1.89) Misses $(1.40) Estimate, Sales $138.74M Beat $126.44M Estimate

PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(1.89) per share which missed the analyst consensus estimate of $(1.40) by 35 percent. This is a 83.5 percent decrease over losses of $(1.03) per share from the same period last year. The company reported quarterly sales of $138.74 million which beat the analyst consensus estimate of $126.44 million by 9.73 percent. This is a 17.18 percent increase over sales of $118.40 million the same period last year.